Retatrutide
LY3437943, LY-3437943
A synthetic peptide acting as a triple agonist for GLP-1, GIP, and glucagon receptors, designed for treating obesity and type 2 diabetes by promoting weight loss and glycemic control.
Completed
PHASE1
NCT05548231
A Study of LY3437943 in Chinese Participants With Obesity Or Overweight
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT05757531
A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT07165028
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06662383
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE1
NCT06982859
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT05916560
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
NA
NCT07226947
Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment
Massachusetts General Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT05936151
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT05445232
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT05931367
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT06003465
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06859268
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT04881760
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT06313528
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06260722
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT04867785
A Study of LY3437943 in Participants With Type 2 Diabetes
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT06808802
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT05929066
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06354660
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE3
NCT07232719
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025